OPTIFAST
Othermedically-supervised weight management program
NCT Number: NCT02635698
Compare percent change in loss of body weight between the OPTIFAST program and a food-based energy-deficit program
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
Alaska Premier Health, Anchorage, Alaska, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
medically-supervised weight management program
low-energy, low-fat diet
Time frame: 26 weeks
Percent change in body weight between Initial Visit/Baseline and 26 weeks
Time frame: 52 weeks
Percent change in body weight between Initial Visit/Baseline and 52 weeks
Time frame: 52 weeks
Percentage of subjects meeting short- and long-term weight loss goals
Time frame: 52 weeks
change in BMI in kg/m^2 from baseline to 52 weeks
Time frame: 52 weeks
Change in 10-year cardiovascular risk score (% likelihood to develop CVD in 10 years)
Société des Produits Nestlé (SPN)
Industry
Opti-WIN: Effectiveness of the Optifast Program Compared With a Reduced-energy Food Based Diet Plan on Body Weight
Acronym: Opti-WIN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04022499
Body Weight, Diabetes Mellitus
Denver, Colorado, United States
View Trial DetailsNCT06926842
Body Weight, Diabetes Mellitus
Cullman, Alabama, United States
View Trial DetailsNCT04293224
Behavior, Behavior, Animal
Davis, California, United States
View Trial DetailsNCT04271735
Arterial Occlusive Diseases, Arteriosclerosis
Bethesda, Maryland, United States
View Trial Details